A Phase 2 interventional study of kisspeptin 112-121 and GnRH in Hypogonadotropic Hypogonadism, sponsored by Stephanie B. Seminara, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Stephanie B. Seminara, MD · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 185 studies in Hypogonadism with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Hypogonadism · United States.
Among the 185 studies in Hypogonadism with a site in United States, this one is the 121st largest by enrollment of the 154 interventional ones that give a count, is one of 7 that started in 2019, is one of 54 in phase 2, and was the 166th registered.
320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.
Browse Hypogonadism studies →12 of the 185 studies in Hypogonadism with a site in United States are open now. Recruiting first, the newest first:
Stephanie B. Seminara, MD · Sites in United States
Ages 18–45 · Women only
University of California, Irvine · Sites in United States
Ages 18+ · Men only
Halozyme Therapeutics · Sites in United States
Ages 12–17 · Men only
Bradley Nindl · Sites in United States
Ages 18–40 · Healthy volunteers
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
185 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 62 · Phase 3 31 · Phase 4 27
First in 1989; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 50 across 243 interventional studies indexed under Hypogonadism.
Median enrollment 45 across the 154 interventional studies, 70 across the 27 observational. Of the 154 that completed or were terminated, 84 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 185 have an industry lead sponsor. The 10 most frequent:
Stephanie B. Seminara, MD is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Stephanie B. Seminara, MD has 6 studies filed under Hypogonadism — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypogonadism with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04301765Seattle Institute for Biomedical and Clinical ResearchImproving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency | 2026-11 |
| NCT06720597University of California, IrvineEndoPAT Device for Endothelial Dysfunction in ED | 2027-01 |
| NCT04049331Seattle Institute for Biomedical and Clinical ResearchTestosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone | 2027-01-30 |
| NCT06455969Bradley NindlAdaptions and Resiliency to Multi-Stressor OpeRations | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 185 studies in Hypogonadism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.
Delivery of Interventions:
On the day of the inpatient study, the subjects will
Inclusion/exclusion criteria:
Confirmed diagnosis of HH with
For women,
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
• Intravenous administration of kisspeptin 112-121; 20 boluses in a 40-hour period. Intravenous administration of GnRH; one bolus.
Drug: kisspeptin 112-121 · Drug: GnRH
20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
Also known as: metastin 45-54
1 intravenous dose of GnRH
Also known as: gonadotropin-releasing hormone
Average Change in Luteinizing Hormone (LH) Pulse Amplitude in Response to Kisspeptin
Change in LH amplitude before, during and after kisspeptin administration
Time frame: 52 hours
Average Change in LH Pulse Frequency in Response to Kisspeptin
Change in LH frequency before and after kisspeptin administration
Time frame: 52 hours
Boston area. 18 participants were consented and screened for eligibility between 5/2019 and 11/2022.
| Milestone | Experimental: Kisspeptin, GnRH |
|---|---|
| Started | 18 |
| Completed | 7 |
| Not completed | 11 |
Change in LH amplitude before, during and after kisspeptin administration
| IU/L | Experimental: Kisspeptin, GnRH |
|---|---|
| Before vs. During | 0.35 ± 0.43 |
| Before vs. After | 0.19 ± 0.30 |
Change in LH frequency before and after kisspeptin administration
| # pulses/hour | Experimental: Kisspeptin, GnRH |
|---|---|
| Average Change in LH Pulse Frequency in Response to Kisspeptin | 0.17 ± 0.27 |
Collected over From time of study consent until removal from study participation (approximately 3 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Kisspeptin, GnRH | 0/18 (0%) | 1/18 (5.6%) | 6/18 (33.3%) |
| Event | Experimental: Kisspeptin, GnRH |
|---|---|
| Rhabdomyolysis after completion of study visitsMusculoskeletal and connective tissue disorders | 1/18 |
| Event | Experimental: Kisspeptin, GnRH |
|---|---|
| FatigueGeneral disorders | 2/18 |
| Hot flashesVascular disorders | 1/18 |
| Skin infectionInfections and infestations | 1/18 |
| DizzinessNervous system disorders | 1/18 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/18 |
| Age, Categorical(Participants) | Experimental: Kisspeptin, GnRH |
|---|---|
| <=18 years | 2 |
| Between 18 and 65 years | 16 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Experimental: Kisspeptin, GnRH |
|---|---|
| Female | 8 |
| Male | 10 |
| Race (NIH/OMB)(Participants) | Experimental: Kisspeptin, GnRH |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 14 |
| More than one race | 1 |
| Unknown or Not Reported | 1 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: Kisspeptin, GnRH |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Aug 2025, 75 months.
Results were first posted in Aug 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: KISS1 protein, human · Gonadotropin-Releasing Hormone
Stephanie B. Seminara, MD